Overview on the use of therapeutic antibodies in drug discovery
- PMID: 22294129
- DOI: 10.1002/0471141755.ph0907s27
Overview on the use of therapeutic antibodies in drug discovery
Abstract
The number of therapeutic antibodies approved by regulatory agencies as novel drugs and the number of antibodies in development has increased significantly. The modular nature of antibody structure has enabled researchers to more predictably design therapeutic antibodies by choosing appropriate functional features most appropriate for a given antibody target and clinical indication. Advances in recombinant antibody technologies have allowed the routine generation of antibodies that can satisfy stringent drug design criteria, such as low immunogenicity, high affinity, target specificity, and commercially viable manufacturing methods. Engineering design opportunities exist for both the variable and the constant regions that encompass, in addition to antigen specificity and affinity, effector functions that mediate immune complex clearance or pharmacokinetics. These are discussed in the context of relevant in vivo and in vitro technologies, such as human IgG transgenic mice, phage display, and biologics manufacturing. Finally, therapeutic antibodies are compared with traditional drugs with respect to target class, selectivity, route of administration, intellectual property issues, and lead discovery and optimization.
Similar articles
-
New technologies in therapeutic antibody development.Curr Opin Pharmacol. 2003 Oct;3(5):544-50. doi: 10.1016/j.coph.2003.05.002. Curr Opin Pharmacol. 2003. PMID: 14559101 Review.
-
Phage display-derived human antibodies in clinical development and therapy.MAbs. 2016 Oct;8(7):1177-1194. doi: 10.1080/19420862.2016.1212149. Epub 2016 Jul 14. MAbs. 2016. PMID: 27416017 Free PMC article. Review.
-
The application of transgenic mice for therapeutic antibody discovery.Methods Mol Biol. 2012;901:137-48. doi: 10.1007/978-1-61779-931-0_8. Methods Mol Biol. 2012. PMID: 22723098
-
Advances in phage display technology for drug discovery.Expert Opin Drug Discov. 2015 Jun;10(6):651-69. doi: 10.1517/17460441.2015.1037738. Epub 2015 Apr 24. Expert Opin Drug Discov. 2015. PMID: 25910798 Review.
-
Phage display-derived peptides as therapeutic alternatives to antibodies.Drug Discov Today. 2004 Jun 15;9(12):525-9. doi: 10.1016/S1359-6446(04)03104-6. Drug Discov Today. 2004. PMID: 15183160 Review.
Cited by
-
Therapeutic Monoclonal Antibodies against Cancer: Present and Future.Cells. 2023 Dec 14;12(24):2837. doi: 10.3390/cells12242837. Cells. 2023. PMID: 38132155 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources